Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Li, Na ^a   Sun, Chaoyang ^a   Zhou, Bo ^a   Xing, Hui ^b   Ma, Ding ^a   Chen, Gang ^a   Weng, Danhui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF ARTS AND SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C; ENDONUCLEASE G; FLUOROURACIL; GLUTATHIONE PEROXIDASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PACLITAXEL; PIRARUBICIN; QUERCETIN; UNCOUPLING PROTEIN 2; ANTINEOPLASTIC AGENT; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; OXIDATIVE STRESS; QUERCETIN; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904349833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100314     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Formica JV, Regelson W (1995) Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 33: 1061-1080. (Pubitemid 26009773)
3. Asselin E, Mills GB, Tsang BK (2001) XIAP regulates Akt activity and caspase- 3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61: 1862-1868. (Pubitemid 32692000)
4. Gates MA, Vitonis AF, Tworoger SS, Rosner B, Titus-Ernstoff L, et al. (2009) Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int J Cancer 124: 1918-1925.
5. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, et al. (2008) Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 upregulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem 105: 1386-1398.
6. Chang YF, Chi CW, Wang JJ (2006) Reactive oxygen species production is involved in quercetin-induced apoptosis in human hepatoma cells. Nutr Cancer 55: 201-209.
7. Nessa MU, Beale P, Chan C, Yu JQ, Huq F (2011) Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res 31: 3789-3797.
8. Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T, et al. (2012) Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res 32: 61-71.
9. Robaszkiewicz A, Balcerczyk A, Bartosz G (2007) Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biol Int 31: 1245-1250. (Pubitemid 47030992)
10. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, et al. (2008) Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68: 8031-8038.
11. Sun C, Li N, Yang Z, Zhou B, He Y, et al. (2013) miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst 105: 1750-1758.
12. Pylvas M, Puistola U, Laatio L, Kauppila S, Karihtala P (2011) Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. Anticancer Res 31: 1411-1415.
13. Lu P, Qiao J, He W, Wang J, Jia Y, et al. (2014) Genome-Wide Gene Expression Profile Analyses Identify CTTN as a Potential Prognostic Marker in Esophageal Cancer. PLoS One 9: e88918.
14. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
15. Gao S, Chen T, Choi MY, Liang Y, Xue J, et al. (2013) Cyanidin reverses cisplatin-induced apoptosis in HK-2 proximal tubular cells through inhibition of ROS-mediated DNA damage and modulation of the ERK and AKT pathways. Cancer Lett 333: 36-46.
16. Wu LL, Chiou CC, Chang PY, Wu JT (2004) Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 339: 1-9. (Pubitemid 37542453)
17. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L (2011) Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 68: 1161-1172.
18. Ramos AM, Aller P (2008) Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines. Biochem Pharmacol 75: 1912-1923.
19. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB (1997) Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 114: 139-140. (Pubitemid 27140094)
20. Gugler R, Leschik M, Dengler HJ (1975) Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9: 229-234.
21. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, et al. (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138: 1615-1621.